Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 1;136(5):473-481.
doi: 10.1001/jamaophthalmol.2018.0504.

Incidence of and Risk Factors Associated With Age-Related Macular Degeneration: Four-Year Follow-up From the ALIENOR Study

Affiliations

Incidence of and Risk Factors Associated With Age-Related Macular Degeneration: Four-Year Follow-up From the ALIENOR Study

Valentine Saunier et al. JAMA Ophthalmol. .

Abstract

Importance: While the prevalence of age-related macular degeneration (AMD) differs according to continents and races/ethnicities, its incidence in the European continent has been scarcely documented.

Objective: To describe the incidence and associated risk factors of AMD in elderly French individuals.

Design, setting, and participants: This population-based cohort study of 963 residents of Bordeaux, France, who were 73 years or older at baseline and participated in the Antioxydants, Lipides Essentiels, Nutrition et Maladies Oculaires (ALIENOR) Study between October 2, 2006, and December 21, 2012. Of 829 participants at risk for incident AMD, 659 (79.5%) were observed for a mean (SD) duration of 3.8 (1.1) years. Data were analyzed from August 2016 to March 2017.

Main outcomes and measures: Age-related macular degeneration was graded from retinal photographs and spectral-domain optical coherence tomography into 5 exclusive stages: no AMD, early AMD1, early AMD2, late atrophic AMD, and late neovascular AMD.

Results: Of the 659 eligible participants, 413 (62.7%) were women, and the mean (SD; range) age was 79.7 (4.4; 73-94) years. A total of 120 incident cases of early AMD and 45 incident cases of advanced AMD were recorded. Incidence rates of early and advanced AMD were 79.9 (95% CI, 66.8-95.5) per 1000 person-years and 18.6 (95% CI, 13.9-24.9) per 1000 person-years, respectively, corresponding to 5-year risks of 32.9% and 8.9%. Incidence of advanced AMD per 1000 eye-years was 1.5 in eyes without any AMD at baseline, 42.4 in those with early AMD1, and 85.1 in those with early AMD2. In multivariate analysis without correction for multiple testing, progression from early to advanced AMD was associated with AMD grade in the fellow eye (hazard ratio [HR] according to grade, 13.0 [95% CI, 2.8-61.2] to 22.5 [95% CI, 2.6-195.9]), having smoked at least 20 pack-years (calculated as number of smoking years × mean number of cigarettes per day / 20; HR, 3.0; 95% CI, 1.4-6.5), and complement factor H (CFH) Y402H genotype (CC genotype: HR, 2.3; 95% CI, 1.0-5.3; TC genotype: HR, 1.5; 95% CI, 0.6-3.7). Incidence of early AMD was associated with early AMD in the fellow eye (early AMD1: HR, 2.6; 95% CI, 1.6-4.2; early AMD2: HR, 5.6; 95% CI, 3.3-9.4) and high plasma high-density lipoprotein cholesterol levels (HR, 1.2; 95% CI, 1.0-1.4).

Conclusions and relevance: In this cohort, AMD incidence rates were similar to those observed in other European populations. This study suggests a high risk for incident early AMD in individuals with high plasma high-density lipoprotein cholesterol levels while confirming the high risk for progression from early to advanced AMD in heavy smokers and carriers of CFH Y402H at-risk genotypes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Merle has received personal fees from Horus Pharma, St Hubert Oméga 3, and Bausch & Lomb. Dr Delyfer has received personal fees from Allergan, Bayer, Novartis, and Laboratoires Théa. Dr Rougier has received personal fees from Allergan, Bausch & Lomb, Bayer, Novartis, Laboratoires Théa, Abbvie, and Zeiss. Dr Amouyel has received personal fees from Takeda, Servier, Total, Fondation Plan Alzheimer, Genoscreen, and Alzoprotect. Dr Dartigues has received grants from Ipsen and Roche. Dr Korobelnik has received personal fees from Alcon, Alimera, Allergan, Bayer, Novartis, Laboratoires Théa, Roche, and Zeiss. Dr Delcourt has received personal fees from Allergan, Bausch & Lomb, Laboratoires Théa, Novartis, and Roche. No other disclosures were reported.

Figures

Figure.
Figure.. Eye-Specific Incidence of Age-Related Macular Degeneration (AMD) According to Age Group and AMD Grade at Baseline
Incidence of advanced AMD calculated as number of cases per 1000 eye-years. Early AMD1 defined as presence of soft distinct drusen without pigmentary abnormalities or of pigmentary abnormalities without large drusen (>125 μm). Early AMD2 defined as presence of soft indistinct drusen and/or reticular pseudodrusen and/or soft distinct drusen associated with pigmentary abnormalities (hyperpigmentation or hypopigmentation). The error bars indicate 95% CIs.

Similar articles

Cited by

References

    1. Bourne RR, Stevens GA, White RA, et al. ; Vision Loss Expert Group . Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339-e349. - PubMed
    1. Wong WL, Su X, Li X, et al. . Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-e116. - PubMed
    1. Mitchell P, Wang JJ, Foran S, Smith W. Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology. 2002;109(6):1092-1097. - PubMed
    1. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997;104(1):7-21. - PubMed
    1. Varma R, Foong AW, Lai MY, Choudhury F, Klein R, Azen SP; Los Angeles Latino Eye Study Group . Four-year incidence and progression of age-related macular degeneration: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2010;149(5):741-751. - PMC - PubMed

Publication types